Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

The novel oral typhoid vaccine M01ZH09 is well tolerated and highly immunogenic in 2 vaccine presentations.

Kirkpatrick BD, Tenney KM, Larsson CJ, O'Neill JP, Ventrone C, Bentley M, Upton A, Hindle Z, Fidler C, Kutzko D, Holdridge R, Lapointe C, Hamlet S, Chatfield SN.

J Infect Dis. 2005 Aug 1;192(3):360-6. Epub 2005 Jun 30.

PMID:
15995948
2.

Optimization of Salmonella enterica serovar typhi DeltaaroC DeltassaV derivatives as vehicles for delivering heterologous antigens by chromosomal integration and in vivo inducible promoters.

Stratford R, McKelvie ND, Hughes NJ, Aldred E, Wiseman C, Curtis J, Bellaby T, Bentley M, Hindle Z, Brennan FR, Chatfield SN, Dougan G, Khan SA.

Infect Immun. 2005 Jan;73(1):362-8.

3.

Expression of heterologous antigens in Salmonella Typhimurium vaccine vectors using the in vivo-inducible, SPI-2 promoter, ssaG.

McKelvie ND, Stratford R, Wu T, Bellaby T, Aldred E, Hughes NJ, Chatfield SN, Pickard D, Hale C, Dougan G, Khan SA.

Vaccine. 2004 Sep 3;22(25-26):3243-55.

PMID:
15308346
4.

Salmonella typhi and S typhimurium derivatives harbouring deletions in aromatic biosynthesis and Salmonella Pathogenicity Island-2 (SPI-2) genes as vaccines and vectors.

Khan SA, Stratford R, Wu T, Mckelvie N, Bellaby T, Hindle Z, Sinha KA, Eltze S, Mastroeni P, Pickard D, Dougan G, Chatfield SN, Brennan FR.

Vaccine. 2003 Jan 17;21(5-6):538-48.

PMID:
12531654
5.

Characterization of Salmonella enterica derivatives harboring defined aroC and Salmonella pathogenicity island 2 type III secretion system (ssaV) mutations by immunization of healthy volunteers.

Hindle Z, Chatfield SN, Phillimore J, Bentley M, Johnson J, Cosgrove CA, Ghaem-Maghami M, Sexton A, Khan M, Brennan FR, Everest P, Wu T, Pickard D, Holden DW, Dougan G, Griffin GE, House D, Santangelo JD, Khan SA, Shea JE, Feldman RG, Lewis DJ.

Infect Immun. 2002 Jul;70(7):3457-67.

7.

Characterization of candidate live oral Salmonella typhi vaccine strains harboring defined mutations in aroA, aroC, and htrA.

Lowe DC, Savidge TC, Pickard D, Eckmann L, Kagnoff MF, Dougan G, Chatfield SN.

Infect Immun. 1999 Feb;67(2):700-7.

9.

Regulation of host immune responses by modification of Salmonella virulence genes.

VanCott JL, Chatfield SN, Roberts M, Hone DM, Hohmann EL, Pascual DW, Yamamoto M, Kiyono H, McGhee JR.

Nat Med. 1998 Nov;4(11):1247-52.

PMID:
9809547
10.

Immune responses in calves immunised orally or subcutaneously with a live Salmonella typhimurium aro vaccine.

Villarreal-Ramos B, Manser J, Collins RA, Dougan G, Chatfield SN, Howard CJ.

Vaccine. 1998 Jan;16(1):45-54.

PMID:
9607008
11.

Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans.

Tacket CO, Sztein MB, Losonsky GA, Wasserman SS, Nataro JP, Edelman R, Pickard D, Dougan G, Chatfield SN, Levine MM.

Infect Immun. 1997 Feb;65(2):452-6.

12.
13.

Regulation of mucosal and systemic antibody responses by T helper cell subsets, macrophages, and derived cytokines following oral immunization with live recombinant Salmonella.

VanCott JL, Staats HF, Pascual DW, Roberts M, Chatfield SN, Yamamoto M, Coste M, Carter PB, Kiyono H, McGhee JR.

J Immunol. 1996 Feb 15;156(4):1504-14.

PMID:
8568254
14.

The role of Th1 and Th2 cells for mucosal IgA responses.

Yamamoto M, Vancott JL, Okahashi N, Marinaro M, Kiyono H, Fujihashi K, Jackson RJ, Chatfield SN, Bluethmann H, McGhee JR.

Ann N Y Acad Sci. 1996 Feb 13;778:64-71. Review.

PMID:
8611017
15.

Mucosal immunity: regulation by helper T cells and a novel method for detection.

Jackson RJ, Marinaro M, VanCott JL, Yamamoto M, Okahashi N, Fujihashi K, Kiyono H, Chatfield SN, McGhee JR.

J Biotechnol. 1996 Jan 26;44(1-3):209-16. Review.

PMID:
8717406
16.

Expression of fragment C of tetanus toxin fused to a carboxyl-terminal fragment of diphtheria toxin in Salmonella typhi CVD 908 vaccine strain.

Gómez-Duarte OG, Galen J, Chatfield SN, Rappuoli R, Eidels L, Levine MM.

Vaccine. 1995 Nov;13(16):1596-602.

PMID:
8578848
17.

Influence of preimmunization with tetanus toxoid on immune responses to tetanus toxin fragment C-guest antigen fusions in a Salmonella vaccine carrier.

Chabalgoity JA, Villareal-Ramos B, Khan CM, Chatfield SN, de Hormaeche RD, Hormaeche CE.

Infect Immun. 1995 Jul;63(7):2564-9.

19.

The development of oral vaccines against parasitic diseases utilizing live attenuated Salmonella.

Chatfield SN, Roberts M, Dougan G, Hormaeche C, Khan CM.

Parasitology. 1995;110 Suppl:S17-24. Review.

PMID:
7784125
20.

Oral vaccine models: multiple delivery systems employing tetanus toxoid.

Jackson RJ, Staats HF, Xu-Amano J, Takahashi I, Kiyono H, Hudson ME, Gilley RM, Chatfield SN, McGhee JR.

Ann N Y Acad Sci. 1994 Aug 15;730:217-34.

PMID:
8080173
21.

Role of hns in the virulence phenotype of pathogenic salmonellae.

Harrison JA, Pickard D, Higgins CF, Khan A, Chatfield SN, Ali T, Dorman CJ, Hormaeche CE, Dougan G.

Mol Microbiol. 1994 Jul;13(1):133-40.

PMID:
7984087
22.
23.

Use of the nirB promoter to direct the stable expression of heterologous antigens in Salmonella oral vaccine strains: development of a single-dose oral tetanus vaccine.

Chatfield SN, Charles IG, Makoff AJ, Oxer MD, Dougan G, Pickard D, Slater D, Fairweather NF.

Biotechnology (N Y). 1992 Aug;10(8):888-92.

PMID:
1368983
24.

Impaired resistance to infection does not increase the virulence of Salmonella htrA live vaccines for mice.

Strahan K, Chatfield SN, Tite J, Dougan G, Hormaeche CE.

Microb Pathog. 1992 Apr;12(4):311-7.

PMID:
1630300
25.

Expression of human IL-1 beta in Salmonella typhimurium. A model system for the delivery of recombinant therapeutic proteins in vivo.

Carrier MJ, Chatfield SN, Dougan G, Nowicka UT, O'Callaghan D, Beesley JE, Milano S, Cillari E, Liew FY.

J Immunol. 1992 Feb 15;148(4):1176-81.

PMID:
1737934
26.

Evaluation of Salmonella typhimurium strains harbouring defined mutations in htrA and aroA in the murine salmonellosis model.

Chatfield SN, Strahan K, Pickard D, Charles IG, Hormaeche CE, Dougan G.

Microb Pathog. 1992 Feb;12(2):145-51.

PMID:
1584006
27.

Construction of a genetically defined Salmonella typhi Ty2 aroA, aroC mutant for the engineering of a candidate oral typhoid-tetanus vaccine.

Chatfield SN, Fairweather N, Charles I, Pickard D, Levine M, Hone D, Posada M, Strugnell RA, Dougan G.

Vaccine. 1992;10(1):53-60.

PMID:
1311488
28.

The involvement of tumor necrosis factor in immunity to Salmonella infection.

Tite JP, Dougan G, Chatfield SN.

J Immunol. 1991 Nov 1;147(9):3161-4.

PMID:
1919009
29.

Synthesis of tetanus toxin fragment C in insect cells by use of a baculovirus expression system.

Charles IG, Rodgers BC, Makoff AJ, Chatfield SN, Slater DE, Fairweather NF.

Infect Immun. 1991 May;59(5):1627-32.

30.

Oral vaccination of calves against experimental salmonellosis using a double aro mutant of Salmonella typhimurium.

Jones PW, Dougan G, Hayward C, Mackensie N, Collins P, Chatfield SN.

Vaccine. 1991 Jan;9(1):29-34.

PMID:
2008797
31.
32.

Use of live attenuated bacteria to stimulate immunity.

Fairweather NF, Chatfield SN, Charles IG, Roberts M, Lipscombe M, Li LJ, Strugnell D, Comerford S, Tite J, Dougan G.

Res Microbiol. 1990 Sep-Oct;141(7-8):769-73. Review. No abstract available.

PMID:
2101467
33.

Oral vaccination of mice against tetanus by use of a live attenuated Salmonella carrier.

Fairweather NF, Chatfield SN, Makoff AJ, Strugnell RA, Bester J, Maskell DJ, Dougan G.

Infect Immun. 1990 May;58(5):1323-6.

34.

Live Salmonella as vaccines and carriers of foreign antigenic determinants.

Chatfield SN, Strugnell RA, Dougan G.

Vaccine. 1989 Dec;7(6):495-8. Review.

PMID:
2481908
35.

Supplemental Content

Loading ...
Support Center